As the global aging process continues to lengthen, aging-related diseases (e.g., chronic obstructive pulmonary disease (COPD), heart failure) continue to plague the elderly population. Aging is a complex biological process involving multiple tissues and organs and is involved in the development and progression of multiple aging-related diseases. At the same time, some of these aging-related diseases are often accompanied by hypoxia, chronic inflammation, oxidative stress, and the increased secretion of the senescence-associated secretory phenotype (SASP). Hypoxia seems to play an important role in the process of inflammation and aging, but is often neglected in advanced clinical research studies. Therefore, we have attempted to elucidate the role played by different degrees and types of hypoxia in aging and aging-related diseases and their possible pathways, and propose rational treatment options based on such mechanisms for reference.

Both reactive oxygen species (ROS) from redox-biology and pro-inflammatory cytokines from innate immunity/and other sources, in addition to their role in redox-biology, and in defense and repair, have long been regarded as potentially harmful factors associated with oxidative stress and inflammatory states. However, their important physiological functions as signaling molecules have been demonstrated to be of importance, also in Geroscience, particularly when ROS are at balanced basal levels (redox-biology) and pro-inflammatory cytokines are at very low levels (cold-inflammaging). Under these conditions, both of these components (alone or in combination) may act as signaling/response molecules involved in regulating/maintaining or restoring adaptive homeostasis during aging, particularly in the early phases of even very-mild non-damaging internal or external environmental stimuli that could nevertheless elicit low-grade warnings-signals for homeostatic stability. If signals potentially perturbing homeostasis persist, the levels of ROS and pro-inflammatory mediators increase resulting in a switch from adaptive to maladaptive responses which may lead to oxidative stress and overt-inflammaging (or even to an overt inflammatory state), thus paving the way to the risks of aging-related diseases (ARDs). Conversely, upon adaptive-responses, low-levels of ROS and very-low-levels of pro-inflammatory-cytokines, alone or in combination, can result in an amplified capacity to prevent or slow-down overt-inflammaging (2-fold to 4-fold increase of pro-inflammatory cytokines) thus maintaining or restoring homeostasis. Therefore, these signaling molecules may also have the sequential incremental potential to prevent or slow the subsequent decline of adaptive homeostasis that will occur later in the lifespan. These scenarios may lead us to conceive of, and conceptualize, both these molecules and their basal-low levels, as well as their dynamics and the time-course of responses, as 'potential important pillars of adaptive-homeostasis in aging' since the earliest phases of the occurrence of any even very- mild environmental potential imbalance.

The aim was to determine whether lipid molecules can be used as potential biomarkers for idiopathic pulmonary arterial hypertension (IPAH), providing important reference value for early diagnosis and treatment. Liquid chromatography–mass spectrometry-based lipidomic assays allow for the simultaneous detection of a large number of lipids. In this study, lipid profiling was performed on plasma samples from 69 IPAH patients and 30 healthy controls to compare the levels of lipid molecules in the 2 groups of patients, and Cox regression analysis was used to identify meaningful metrics, along with receiver operator characteristic curves to assess the ability of the lipid molecules to predict the risk of disease in patients. Among the 14 lipid subclasses tested, 12 lipid levels were significantly higher in IPAH patients than in healthy controls. Free fatty acids (FFA) and monoacylglycerol (MAG) were significantly different between IPAH patients and healthy controls. Logistic regression analysis showed that FFA (OR: 1.239, 95%CI: 1.101, 1.394, p < 0.0001) and MAG (OR: 3.711, 95%CI: 2.214, 6.221, p < 0.001) were independent predictors of IPAH development. Among the lipid subclasses, FFA and MAG have potential as biomarkers for predicting the pathogenesis of IPAH, which may improve the early diagnosis of IPAH.

Objectives The aim of this study was to investigate the combined effects of a novel survivin promoter-based conditionally replicating adenovirus (CRAd-S.RGD) plus cis-diamminedichloroplatinum (cisplatin, CDDP) in ovarian cancer in vitro and in vivo. Methods The viability of human ovarian cancer cell line SKOV3 was determined by MTT assay following the infection with different doses of CRAd-S.RGD, either alone or in combination with CDDP. The antitumor efficacies and survival curves were evaluated at the end of the treatment regimens with the subcutaneous administration of CRAd-S.RGD, CDDP, combined therapy of CRAd-S.RGD plus CDDP, or phosphate-buffered saline in a SKOV3 xenograft animal model. Furthermore, the apoptosis rate of tumor tissues in mice was determined subsequent to the treatments. Results In vitro, the CRAd-S.RGD destroyed SKOV3 cells by oncolysis in a dose-dependent manner, and the viability of SKOV3 cells was significantly lower in the combined-therapy group than that in the individual-therapy groups. In vivo, enhanced tumor inhibition and animal survival rates were obtained in a synergistic manner with CRAd-S.RGD plus CDDP, as compared with the treatment with CRAd-S.RGD or CDDP alone. There was an increase in the apoptosis rate of the cells following the combined therapy. The results clearly demonstrated that there was a synergistic effect in the combination of CRAd-S.RGD and CDDP in increased therapeutic efficacy. Similar therapeutic efficacy could be obtained with CRAd-S.RGD plus CDDP at 2 lower doses that minimized the drug toxicity to host tissues. Conclusions The strategy of CRAd-S.RGD in combination with CDDP was a potential therapeutic modality for the therapy in ovarian cancer. Abbreviations CDDP - cisplatin, cis-diamminedichloroplatinum, CRAd - conditionally replicating adenovirus, CRAd-survivin - the survivin promoter-based conditionally replicating adenovirus, CRAd-S.RGD - CRAd–survivin-RGD4C, MOI - multiplicity of infection, PBS - phosphate-buffered saline, PI - propidium iodide